| Schedule of Segment Information |
Net revenue, cost of revenues, operating expenses, operating loss,
finance income, other income (expenses) and net loss by diverse operations for the year ended December 31, 2025, and 2024 were as follows:
| For year ended December
31, 2025 | |
Sales
of medical
and other
related products | | |
Research and
development of
pancreatic
cancer early
detection
services | | |
Research and
development of
sales of contact
lenses | | |
Corporate
unallocated | | |
Consolidated | |
| Net revenues | |
$ | 561,817 | | |
$ | — | | |
$ | 35,000 | | |
$ | — | | |
$ | 596,817 | |
| Cost of revenues | |
| (401,264 | ) | |
| — | | |
| (28,143 | ) | |
| — | | |
| (429,407 | ) |
| Gross profit | |
| 160,553 | | |
| — | | |
| 6,857 | | |
| — | | |
| 167,410 | |
| Total operating expenses | |
| (444,208 | ) | |
| (143,927 | ) | |
| (1,805,720 | ) | |
| (3,045,276 | ) | |
| (5,439,131 | ) |
| Operating loss | |
| (283,655 | ) | |
| (143,927 | ) | |
| (1,798,863 | ) | |
| (3,045,276 | ) | |
| (5,271,721 | ) |
| Finance income, net | |
| 18,397 | | |
| — | | |
| — | | |
| 61,765 | | |
| 80,162 | |
| Other income (expenses), net | |
| 46,942 | | |
| — | | |
| — | | |
| (139 | ) | |
| 46,803 | |
| Change in fair value of warrant liabilities | |
| — | | |
| — | | |
| — | | |
| (3,168,091 | ) | |
| (3,168,091 | ) |
| Income tax expenses | |
| 1,531 | | |
| — | | |
| — | | |
| — | | |
| 1,531 | |
| Net loss | |
| (216,785 | ) | |
| (143,927 | ) | |
| (1,798,863 | ) | |
| (6,151,741 | ) | |
| (8,311,316 | ) |
| | |
| | | |
| | | |
| | | |
| | | |
| | |
| As of December 31, 2025 | |
| | | |
| | | |
| | | |
| | | |
| | |
| Identifiable long-lived assets | |
| 67,810 | | |
| 1,722,600 | | |
| 887,139 | | |
| — | | |
| 2,677,549 | |
| Total assets | |
$ | 2,337,152 | | |
$ | 1,722,600 | | |
$ | 887,139 | | |
$ | 8,832,506 | | |
$ | 13,779,397 | |
| For year ended December 31, 2024 | |
Sales of
medical
and other
related products | | |
Research and
development of
pancreatic
cancer early
detection
services | | |
Research and
development of
sales of contact
lenses | | |
Corporate
unallocated | | |
Consolidated | |
| Net revenues | |
$ | 510,360 | | |
$ | — | | |
$ | — | | |
$ | — | | |
$ | 510,360 | |
| Cost of revenues | |
| (355,004 | ) | |
| — | | |
| — | | |
| — | | |
| (355,004 | ) |
| Gross profit | |
| 155,356 | | |
| — | | |
| — | | |
| — | | |
| 155,356 | |
| Total operating expenses | |
| (447,642 | ) | |
| (53,678 | ) | |
| (469,158 | ) | |
| (646,808 | ) | |
| (1,617,286 | ) |
| Operating loss | |
| (292,286 | ) | |
| (53,678 | ) | |
| (469,158 | ) | |
| (646,808 | ) | |
| (1,461,930 | ) |
| Finance income, net | |
| 10,068 | | |
| — | | |
| — | | |
| 968 | | |
| 11,036 | |
| Other income (expenses), net | |
| 64,444 | | |
| — | | |
| — | | |
| (29 | ) | |
| 64,415 | |
| Income tax expenses | |
| (25,080 | ) | |
| — | | |
| — | | |
| — | | |
| (25,080 | ) |
| Net loss | |
| (242,854 | ) | |
| (53,678 | ) | |
| (469,158 | ) | |
| (645,869 | ) | |
| (1,411,559 | ) |
| | |
| | | |
| | | |
| | | |
| | | |
| | |
| As of December 31, 2024 | |
| | | |
| | | |
| | | |
| | | |
| | |
| Identifiable long-lived assets | |
| 88,077 | | |
| 1,769,000 | | |
| 911,035 | | |
| — | | |
| 2,768,112 | |
| Total assets | |
$ | 2,219,996 | | |
$ | 1,769,000 | | |
$ | 911,035 | | |
$ | 1,964,195 | | |
$ | 6,864,226 | |
|